Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab Journal Article
| Authors: | Drill, E.; Qiu, A.; Shapouri, S.; Tu My, T.; Ravelo, A.; Schade, J.; Dawson, K.; Matasar, M. |
| Article Title: | Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab |
| Abstract: | INTRODUCTION: A subcutaneous (SC) formulation of the anti-CD20 monoclonal antibody, rituximab (Rituxan), is approved in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Rituximab-SC (R-SC) has been associated with time and clinic resource savings vs the original intravenous formulation (R-IV). Insight into the resource implications of widening R-SC adoption in a US oncology setting is needed. METHODS: A single-institution, retrospective observational analysis was conducted in adult patients with DLBCL, FL, or CLL. The primary outcome measure was chair occupancy time (difference between patient room-in and room-out times). Prescribing patterns were a secondary outcome. RESULTS: Overall, 1190 patients were analyzed (treatment time frame: pre-R-SC adoption: n = 490 [41%], pre- and post R-SC adoption: n = 189 [16%], post R-SC adoption: n = 511 [43%]). Of the patients in the post-R-SC period, 374 (73%) received R-IV, 52 (10%) received R-IV and R-SC, and 85 (17%) received R-SC. When administered, R-SC reduced combination therapy chair time vs R-IV by a mean 37% (93.2 minutes; P < .001). Monotherapy (any route) reduced chair time vs combination by a mean 35.2 minutes (P < .001), with a further 40.2-minute reduction with R-SC (P < .001), representing 62% (133.4-minute) total chair time savings vs R-IV. Doctors were more likely to prescribe R-SC to patients with FL than DLBCL. CONCLUSIONS: R-SC is associated with significantly reduced chair time vs R-IV in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden. |
| Keywords: | united states; time factors; length of stay; injections, subcutaneous; descriptive statistics; retrospective design; health services accessibility; lymphoma, b-cell -- drug therapy; nonexperimental studies; record review; oncologic care; lymphoma, non-hodgkin's -- drug therapy; leukemia, lymphocytic, chronic -- drug therapy; administration, intravenous; human; health resource utilization; patient care -- evaluation; rituximab -- administration and dosage; organizational efficiency -- evaluation; prescribing patterns -- evaluation; crowding |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 35 |
| Issue: | 12 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2021-12-01 |
| Start Page: | 804 |
| End Page: | 811 |
| Language: | English |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI: | 10.46883/2021.25920935 |
| PUBMED: | 35089000 |
| DOI/URL: | |
| Notes: | Accession Number: 154164388 -- Entry Date: 20211225 -- Revision Date: 20211225 -- Publication Type: Article; research; tables/charts -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8712059. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work